KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Free Cash Flow: 2009-2024

Historic Free Cash Flow for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $468.4 million.

  • Halozyme Therapeutics' Free Cash Flow rose 54.20% to $175.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $602.4 million, marking a year-over-year increase of 53.40%. This contributed to the annual value of $468.4 million for FY2024, which is 25.47% up from last year.
  • Per Halozyme Therapeutics' latest filing, its Free Cash Flow stood at $468.4 million for FY2024, which was up 25.47% from $373.3 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Free Cash Flow registered a high of $468.4 million during FY2024, and its lowest value of $53.0 million during FY2020.
  • Moreover, its 3-year median value for Free Cash Flow was $373.3 million (2023), whereas its average is $358.5 million.
  • Per our database at Business Quant, Halozyme Therapeutics' Free Cash Flow surged by 462.76% in 2021 and then declined by 21.51% in 2022.
  • Yearly analysis of 5 years shows Halozyme Therapeutics' Free Cash Flow stood at $53.0 million in 2020, then surged by 462.76% to $298.0 million in 2021, then dropped by 21.51% to $233.9 million in 2022, then skyrocketed by 59.60% to $373.3 million in 2023, then rose by 25.47% to $468.4 million in 2024.